Press Releases

Read Regulatory and non-regulatory press releases

  • All
  • Non-Regulatory
  • Regulatory
Regulatory

MPI’s spinout Oncology Venture announces positive interim results from a Phase 1/2 DRP guided study of LiPlaCis in heavily pretreated breast cancer patients

Regulatory

MPI’s spinout Oncology Venture will execute license to multi TKI phase 3 compound

Non-Regulatory

Drug response prediction in high-risk multiple myeloma – prediction of melphalan and bortezomib response.

Non-Regulatory

Result of evaluation of DRP for TKI drug from Big Pharma available third week of January 2018

Non-Regulatory

MPI Announces registration of trademark for DRP

Regulatory

MPI – LiPlaCis Phase 2 Recruitment Ongoing in DRP Screened Breast Cancer Patients: Relevant Clinical Benefits in 3 out of 5 Treated Patients

Regulatory

MPI: MPI publishes Half-year Report for the first half of 2017

Non-Regulatory

MPI: DRP to be evaluated in 6 to 7 prospective studies

Non-Regulatory

MPI: 2X Oncology’s CEO, George O. Elston’s newsletter to shareholders

Non-Regulatory

MPI – Investor Analysis of Oncology Venture Sweden AB

Non-Regulatory

MPI: Artikel om MPI og Oncology Venture i Medwatch

Regulatory

MPI: OV to evaluate the potential of in-licensing a small molecule compound for development in cancer from a major Pharmaceutical company

Regulatory

MPI – Last day of trading in paid subscription shares

Regulatory

MPI: Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 – 2X-121

Regulatory

MPI raised SEK 10,3 million in rights issue

Non-Regulatory

Cancer response to OV’s LiPlaCis successfully predicted in early data by MPIs DRP technology

Regulatory

Medical Prognosis Institute A/S Announces Start of Subscription Period for Rights Issue

Non-Regulatory

MPI: 2X Oncology Inc. presents at Jefferies Global Healthcare Conference (live webcast)

Non-Regulatory

MPI – OV’s spinout – 2X Oncology Obtains US IND for 2X-111

Regulatory

MPI – The efficacy of chemotherapy with epirubicin, one the of most used drugs in Breast Cancer can now be predicted by DRP – Poster published at ASCO